Company Profile
OncoTherapy Science provides research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia
In Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company's pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer
Phase II clinical trials for the treatment of bladder cancer. Its portfolio also includes S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer, S-588210, which is in Phase I clinical trials for the treatment of solid tumor, and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer.
Additionally, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma An anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. Incorporated in 2001, OncoTherapy Science is headquartered in Kawasaki, Japan.